Everything you need to know about Evorel Conti patches

Continuous combined HRT means that oestrogen and progestogen are taken together every day without a break, rather than in a sequential pattern. Sequential HRT, by contrast, involves taking progestogen for only part of the cycle, which produces a monthly withdrawal bleed. Continuous combined therapy is designed for women who are postmenopausal and is intended to be bleed-free. Evorel Conti is a continuous combined HRT patch, meaning both hormones are delivered through the skin at the same time, every day.

Partially. The estradiol in Evorel Conti is body-identical, meaning it has the same chemical structure as the oestrogen produced naturally by the body. The progestogen component, norethisterone, is synthetic. It is included specifically to protect the womb lining and is necessary for women who have not had a hysterectomy. Body-identical oestrogen is the form recommended in current UK clinical guidance and is the standard prescribed at Menopause Care.

Evorel Conti is a safe and well-established form of HRT for many postmenopausal women. Because the hormones are absorbed transdermally rather than taken orally, they bypass the liver, which is associated with a lower risk of blood clots compared to oral oestrogen tablets. As with all HRT, the balance of benefits and risks is individual and should be discussed with your doctor in the context of your full medical history. Your clinician will help you determine whether Evorel Conti is the most appropriate option for you.

There is no clinical evidence that Evorel Conti causes weight gain. Some women notice temporary bloating or fluid retention when starting HRT, but this typically settles within the first few weeks to months as the body adjusts to the new hormone levels. Weight changes around menopause are primarily driven by hormonal shifts, changes in metabolism, and lifestyle factors rather than by HRT itself. In fact, stabilising oestrogen levels through HRT can support metabolic function and help prevent the changes in body composition that often accompany menopause. If bloating or fluid retention persists beyond three months, it is worth discussing with your clinician, as a formulation adjustment may help.

Evorel Conti is designed to prevent bleeding. However, some women experience light spotting or irregular bleeding in the first few months of use as the body adjusts to continuous combined therapy. This is relatively common and usually resolves on its own. If you experience persistent irregular bleeding after six months, or heavy bleeding at any point, you should speak to your doctor promptly to rule out other causes.

Light spotting in the first three to six months is generally an expected part of the adjustment period and does not usually require urgent action. However, any heavy bleeding, or any bleeding that begins or continues beyond six months of use, should be assessed by a doctor. Your clinician will want to rule out causes unrelated to the HRT, and may review whether the current formulation or dose is the right fit for you.

No. Evorel Conti is formulated at a fixed dose and is not designed to be doubled. If your symptoms are not adequately controlled on a single patch, the right approach is to speak to your doctor about adjusting your treatment, which may involve a different formulation, dose, or delivery method, rather than applying an additional patch. Always consult your clinician before making any changes to your HRT.

Yes. Evorel Conti patches are available as part of the medication credit on our plans and are a commonly prescribed treatment. The final prescribing decision will always rest with your clinician, who will discuss your options during your appointment and agree a treatment plan with you. We are not able to guarantee any specific prescription in advance of a consultation.

Evorel Sequi is a sequential combined HRT patch designed for women who are still in perimenopause and are likely to be having, or have recently had, periods. It delivers oestrogen continuously but progestogen only for part of the cycle, which produces a monthly withdrawal bleed. Evorel Conti is for postmenopausal women and delivers both hormones continuously, without a bleed. The decision about when to transition from sequential to continuous combined therapy is an individual one, based on how long it has been since your last period, and is something your clinician will guide you through.